Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

INTRODUCTION: Malignant mesothelioma (MM) is an aggressive disease with limited therapeutic options. In preclinical models, vascular endothelial growth factor (VEGF) stimulates MM proliferation. In MM patients, higher plasma VEGF levels correlate inversely with survival. Cediranib is an orally admin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lung Cancer
Autori principali: Campbell, Nicholas P., Kunnavakkam, Rangesh, Leighl, Natasha, Vincent, Mark D., Gandara, David R., Koczywas, Marianna, Gitlitz, Barbara J., Agamah, Edem, Thomas, Sachdev P., Stadler, Walter M., Vokes, Everett E., Kindler, Hedy L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319647/
https://ncbi.nlm.nih.gov/pubmed/22831987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.06.011
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi